Third, the augmentation of G6PD activity—either through pharmacological intervention such as dichloroacetate, DCA,38,39 or genetic means to increase G6PD activity or PPP flux40—bestows an explicit protective advantage against cardiac hypertrophy. This evidence concerns the gene G6PD and cardiac hypertrophy.